Genexine Changes Phase 2 and 3 Clinical Trial Plans for COVID-19 Vaccine

[Asia Economy Reporter Junho Hwang] Genexine announced on the 30th that it has applied for a change in the Phase 2/3 clinical trial plan for its COVID-19 preventive DNA vaccine (GX-19N).

Genexine changed the target population from healthy adults to adults who have previously been vaccinated, shifting the strategy to a clinical trial aimed at verifying the protective efficacy as a booster shot (additional vaccination).

The company explained, "Through conducting global Phase 2/3 clinical trials, we expect to demonstrate the protective efficacy of GX-19N compared to placebo via T-cell immunity and verify the vaccine's effectiveness against breakthrough infections."